Going Back to the Heart of Cardiology: A Virtual Medscape Cardiology/theHeart.org Conference for Practicing Physicians 

DECEMBER 8–10 | DECEMBER 15–17

 

ALL SPONSORED PRESENTATIONS ARE NON-CME


 

MONDAY, DECEMBER 7, 2020 | 7:00 pm – 8:00 pm EST

The Next Horizon in the Heart Failure Treatment Paradigm for Patients With HFrEF

SPEAKER: Karthik Linganathan, MD 

Learning Objectives:

  • Highlight the prevalence, burden, and risk of heart failure in the United States 
  • Review the indications, limitations for use, and contraindications for dapagliflozin 
  • Understand the effects of dapagliflozin in patients with heart failure-reduced ejection fraction (HFrEF) 
  • Describe the effects of dapagliflozin on HF-related outcomes 
  • Discuss practical considerations regarding the use of SGLT2 inhibitors 
  • Understand the stepwise approach to the use of dapagliflozin in patients with HFrEF at risk for CV death or hospitalization for heart failure 
SPONSORED BY: AstraZeneca

 


 

TUESDAY, DECEMBER 8, 2020 | 12:30 pm – 1:15 pm EST

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C 

SPEAKER: Guy L. Mintz, MD, FACC, FACP, FNLA, FASPC 

The session will cover the following information:

  • Cardiovascular disease and its mortality and morbidity
  • Unique mechanism of action for two treatment options
  • Efficacy data for two treatment options
  • Safety data for two treatment options
  • Overview of the ongoing Outcomes trial
SPONSORED BY: Esperion Therapeutics

 


 

THURSDAY, DECEMBER 10, 2020 | 12:30 pm – 1:30 pm EST

Clinical Considerations in Stroke or Transient Ischemic Attack  

SPEAKER: John Venditto, MD, MBA, FACC

Learning Objectives:

  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial
SPONSORED BY: AstraZeneca

 


 

MONDAY, DECEMBER 14, 2020 | 7:00 pm – 7:45 pm EST

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C 

SPEAKER: Jan L. McAlister, DNP, APRN, CLS

The session will cover the following information:

  • Cardiovascular disease and its mortality and morbidity
  • Unique mechanism of action for two treatment options
  • Efficacy data for two treatment options
  • Safety data for two treatment options
  • Overview of the ongoing Outcomes trial
SPONSORED BY: Esperion Therapeutics

 


 

THURSDAY, DECEMBER 17, 2020 | 12:30 pm – 1:30 pm EST

Clinical Considerations across the Spectrum of High Risk Coronary Artery Disease and Stroke 

SPEAKER: John Venditto, MD, MBA, FACC 

The session will cover the following information:

  • Describing the risk spectrum across the spectrum of CAD
  • The role of platelets across the spectrum of CAD
  • The role of antiplatelets in patients with CAD at high risk of CV events, ACS and patients with a history of MI.
SPONSORED BY: AstraZeneca

 


 

Register for a sponsored presentation now to receive 50% off of your full conference registration and we'll match your donation. You will receive your discount code upon completing your sponsored presentation registration.